Efficacy and Safety Study of JNJ-32729463 for Treating Complicated Skin and Skin Structure Infections Compared to Linezolid (Zyvox)

Complicated Skin and Skin Structure Infections Clinical Trial

Official title:
A Randomized, Controlled, Double-Blind, Double Dummy, Multicenter Phase 2 Study of the Safety/Tolerability and Efficacy of JNJ-32729463 Compared With Linezolid (Zyvox) for the Treatment of Complicated Skin and Skin Structure Infection

Status Completed

Clinical Trial Summary

The purpose of this study is to determine the clinical efficacy, safety, and tolerability of a 250 mg BID oral dose of JNJ-32729463 compared with linezolid in subjects with complicated skin and skin structure infections (cSSSIs).

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Communicable Diseases
Complicated Skin and Skin Structure Infections
Infection

Clinical Trial Details

NCT number	NCT01128530
Study type	Interventional
Source	Furiex Pharmaceuticals, Inc
Contact
Status	Completed
Phase	Phase 2
Start date	June 2010
Completion date	January 2011

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02288234` - Telavancin Observational Use Registry (TOUR)
Completed	`NCT01072539` - Study Evaluating The Safety And Effectiveness In Subjects With Tigecycline Treatment
Completed	`NCT00683332` - Post-Marketing Study Of The Safety Of Tygacil (Tigecycline)	N/A
Terminated	`NCT01104662` - Study of Daptomycin Safety and Efficacy for Complicated Skin and Skin Structure Infections (cSSSI) and Bacteremia in Renal Impairment	Phase 4